Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Rivaroxaban). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Kinexa 2.5 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Rivaroxaban 2.5 mg: The recommended dose is 2.5 mg twice daily. Patients should also take a daily dose of 75 to 100 mg Aspirin, or a daily dose of 75 to 100 mg Aspirin in addition to either a daily dose of 75 mg clopidogrel or a standard daily dose of ticlopidine. Rivaroxaban 10 to 20 mg: Nonvalvular Atrial Fibrillation: For patients with Creatinine Clearance above 50 mL/min, the dose is 20 mg orally, once daily with the evening meal. For patients with Creatinine Clearance of 15 to 50 mL/min, the dose is 15 mg orally, once daily with the evening meal. Treatment of DVT and PE: 15 mg orally twice daily with food for the first 21 days for the initial treatment of acute DVT or PE. After the initial treatment period, 20 mg orally once daily with food for the remaining treatment. Prevention of recurrence of DVT and PE: 20 mg once daily with food. Prophylaxis of DVT following hip replacement surgery: 10 mg once daily for 35 days. Prophylaxis of DVT following knee replacement surgery: 10 mg once daily for 12 days. It may be taken with or without food.
Side Effects
Rafter commonly increases the risk of bleeding. It may also cause a spinal or epidural hematoma, and stopping the medicine too early can raise the risk of stroke in people with nonvalvular atrial fibrillation.
Cautions & Contraindications
Warnings & Precautions
Early discontinuation of Rafter, unless adequate alternative anticoagulation is given, increases the risk of thrombotic events. Rafter can increase the risk of bleeding, which may be fatal, in patients with certain risk factors: bleeding disorders, uncontrolled severe arterial hypertension, gastrointestinal disease (such as inflammatory bowel disease, oesophagitis, gastritis, and gastroesophageal reflux disease), vascular retinopathy, bronchiectasis, or a history of pulmonary bleeding. Patients undergoing neuraxial anesthesia (spinal or epidural anesthesia) or spinal puncture should be monitored for signs or symptoms of neurological impairment, since epidural or spinal hematoma can occur. Rafter is not recommended for patients with pulmonary embolism who are hemodynamically unstable or who may need thrombolysis or pulmonary embolectomy.
Contraindications
It is contraindicated in patients with known hypersensitivity of Rivaroxaban or any of the excipients of the product. It is also contraindicated in patients with active pathological bleeding.